Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trial.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D053264:B-Cell Activating Factor / Q000037:antagonists & inhibitors* / Q000276:immunology*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D018579:Patient Selection
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor; C505719:TNFSF13B protein, human; C511911:belimumab